In our recent publication, the Ingress-Health RWE team, together with clinical experts, analyzed a big German claims dataset with >8 million insured to explore unmet needs in patients with Inflammatory Bowel disease not treated with biologics. The team identified a substantial percentage of patients who suffer from active disease and/or steroid dependency, and the majority of them – not in line with guidelines – receives a steroid monotherapy. The study confirms that an improvement of the treatment of these patients is needed.

The publication can be assessed here

For more information, please contact Thomas Wilke – thomas.wilke@ingress-health.com